Fig. 1: Mel44 clinical trial design and long-term outcomes analysis. | Nature Communications

Fig. 1: Mel44 clinical trial design and long-term outcomes analysis.

From: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Fig. 1

The Mel44 clinical trial was designed to evaluate immunologic and clinical outcomes after vaccination with either of two peptide vaccine formulations, and with or without a dose of cyclophosphamide pretreatment. A Protocol schema (B) 2 × 2 design to perform comparisons of Arms A and B (12 class I peptides (12MP) plus tetanus helper peptide) to Arms C and D (12 class I peptides (12MP) plus 6 melanoma helper peptides (6MHP)), as well as comparisons of Arms A + C (no Cy) to Arms B + D (+Cy). Panel B was created with BioRender.com.

Back to article page